Attention deficit hyperactivity disorder (ADHD)
development · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A neurodevelopmental disorder of persistent inattention and/or hyperactivity-impulsivity causing functional impairment across settings and present before age 12. Diagnosis is clinical; management combines behavioural and, where needed, pharmacological measures.
Red flags
- Cardiac symptoms, syncope or family history of sudden cardiac death before stimulants
- Emergent suicidal ideation (notably with atomoxetine)
- Significant growth faltering on treatment
- New tics, psychosis or severe mood disturbance
Assessment
Differential diagnosis
- Normal age-appropriate activity level
- Learning disability or specific learning disorder
- Autism spectrum disorder
- Anxiety, depression or trauma/attachment disorder
- Hearing impairment or absence seizures
- Sleep disorder (including OSA)
- Thyroid dysfunction or substance effects
Investigations
- Symptom and impairment history across at least two settings (home and school)
- Standardised rating scales (e.g. Conners, SNAP-IV) from parents and teachers
- Developmental, family, sleep and mental health history
- Baseline height, weight, pulse and blood pressure before stimulants
- Hearing/vision screen and exclusion of absence seizures if suspected
- Cardiac history and ECG only if cardiac red flags or family history of sudden death
Management
- Confirm symptoms cause impairment in 2+ settings and predate age 12
- Collect multi-informant rating scales and school information
- Exclude mimics (sleep, hearing, anxiety, seizures, learning disorder)
- Provide psychoeducation and first-line behavioural/parent-training support
- Record baseline height, weight, pulse and BP before any medication
- Start stimulant (methylphenidate first line) if impairment persists and titrate to effect
- Monitor growth, cardiovascular parameters, appetite, sleep and mood at each review
- Switch to lisdexamfetamine or non-stimulant (atomoxetine/guanfacine) if poor response/tolerability
- Coordinate school support and review need for ongoing treatment periodically
Drugs & doses
Methylphenidate immediate-release 5 mg PO once-twice daily, titrate to ~0.5-1 mg/kg/dose (modified-release preferred for adherence)
Lisdexamfetamine 30 mg PO once daily (second-line stimulant, titrate by response)
Atomoxetine 0.5 mg/kg/day PO initially, increase to target ~1.2 mg/kg/day (max 1.8 mg/kg or 100 mg)
Guanfacine modified-release 1 mg PO once daily, titrate ~0.05-0.12 mg/kg/day
Disposition
Specialist (paediatric or CAMHS) diagnosis and medication initiation; shared-care monitoring with primary care and school.
Complications & pitfalls
- Academic underachievement and school exclusion
- Low self-esteem, anxiety and depression
- Accidental injury and, later, substance misuse
- Stimulant effects: appetite/growth suppression, insomnia, raised BP/pulse
Exam pearls
- Diagnosis requires impairment across settings, not just at home or school alone
- Plot growth and monitor BP/pulse at every medication review
- A stimulant drug holiday can be considered if growth suppression is marked
- Treat coexisting sleep disorder and anxiety as they amplify symptoms
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.